Key result
Reinitiating DOAC therapy after intracranial hemorrhage in atrial fibrillation patients lowered all-cause mortality risk compared to withholding treatment, without significantly increasing ICH recurrence.
Why the study?
Does reinitiating DOAC therapy reduce all-cause mortality in patients with atrial fibrillation who have experienced an intracerebral hemorrhage?
Does reinitiating DOAC therapy reduce all-cause mortality in patients with atrial fibrillation who have experienced an intracerebral hemorrhage?
Answers are grounded in this paper and cite their sources.
Reinitiating DOACs after ICH in AF patients appears safe and reduces mortality, with optimal timing stratified by ICH severity (within 14 days for low severity, 28 days for high severity).
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
So-Ryoung Lee (2025) conducted an editorial in Atrial fibrillation with prior intracerebral hemorrhage. DOAC reinitiation vs. Withholding antithrombotic treatment was evaluated on All-cause mortality. Reinitiating DOAC therapy after intracranial hemorrhage in atrial fibrillation patients lowered all-cause mortality risk compared to withholding treatment, without significantly increasing ICH recurrence.
Synapse has enriched 10 related papers. Consider them for comparative context: